J.P. Morgan Keeps Their Hold Rating on Surgery Partners (SGRY)

J.P. Morgan analyst Benjamin Rossi maintained a Hold rating on Surgery Partners yesterday and set a price target of $14.00. The company’s shares closed yesterday at $11.49.

End of Quarter Sale - 50% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Rossi covers the Healthcare sector, focusing on stocks such as US Physical Therapy, HCA Healthcare, and Tenet Healthcare. According to TipRanks, Rossi has an average return of 4.5% and a 61.54% success rate on recommended stocks.

Surgery Partners has an analyst consensus of Strong Buy, with a price target consensus of $19.68, a 71.28% upside from current levels. In a report released today, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $11.50 price target.

Based on Surgery Partners’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $885 million and a GAAP net loss of $15 million. In comparison, last year the company earned a revenue of $864.4 million and had a GAAP net loss of $108.5 million

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SGRY in relation to earlier this year. Earlier this month, Jennifer Baldock, the Chief Admin & Dev Officer of SGRY sold 5,798.00 shares for a total of $76,359.66.